![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » UK Outlines Plan for Drug Imports in Case of a No-Deal Brexit
UK Outlines Plan for Drug Imports in Case of a No-Deal Brexit
August 12, 2019
The UK has come up with a plan for authorizing imports of pharmaceutical products in case it leaves the EU on October 31 without a Brexit deal in place.
The guidance provides a detailed description of the process to convert Parallel Distribution Notices (PDNs) – EMA confirmations required to distribute an authorized medicine from one EU member state to another free of marketing authorization — into UK Parallel Import Licenses (PILs) in the event of a no-deal Brexit.
PDN holders can opt-in to the fee-free conversion process for all or some of their PDNs by notifying the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in a process the agency says requires “minimal information.”
If companies choose not to opt-in, their products will no longer be licensed for the UK market starting Nov. 1.
Upcoming Events
-
21Oct